Metabolic Syndrome and Periodontitis: Is Oxidative Stress a Common Link? by Bullon, Pedro et al.
503
DOI: 10.1177/0022034509337479
Received May 28, 2008; Last revision September 19, 2008; 
Accepted November 13, 2008
P. Bullon1, J.M. Morillo1, M.C. Ramirez-
Tortosa2, J.L. Quiles3, H.N. Newman4, 
and M. Battino5*
1Deptartment of Periodontology, Dental School, University 
of Sevilla, Spain; 2Institute of Nutrition and Food Technology, 
Department of Biochemistry and Molecular Biology II, 
University of Granada, Spain; 3Institute of Nutrition and 
Food Technology, Department of Physiology, University of 
Granada, Spain; 4University College London, UK; and 
5Institute of Biochemistry, Faculty of Medicine, Università 
Politecnica delle Marche, Via Ranieri, 65, 60100 Ancona, 
Italy; *corresponding author, m.a.battino@univpm.it
J Dent Res 88(6):503-518, 2009
AbstrAct
A review of pathological mechanisms that can 
explain the relationship between periodontitis 
and cardiovascular disease (CVD) is necessary to 
improve the management of both conditions. 
Metabolic syndrome is a combination of obesity, 
hypertension, impaired glucose tolerance or diabe-
tes, hyperinsulinemia, and dyslipidemia. All these 
have been examined in recent years in terms of their 
relationship to periodontitis. Reviewed data indicate 
an association between some of them (body mass 
index, high-density lipoprotein-cholesterol [HDL-C], 
triglycerides, high blood pressure, among others) 
and periodontitis. Oxidative stress may act as a 
potential common link to explain relationships 
between each component of metabolic syndrome 
and periodontitis. Both conditions show increased 
serum levels of products derived from oxidative 
damage, with a pro-inflammatory state likely influ-
encing each other bidirectionally. Adipocytokines 
might modulate the oxidant/anti-oxidant balance in 
this relationship.
Key words:  metabolic syndrome, oxidative 
stress, periodontitis, hypertension, dyslipidemia, 
insulin resistance.
Metabolic syndrome and 
Periodontitis: Is oxidative  
stress a common Link?
INtrodUctIoN
cardiovascular disease (CVD) is the major cause of death in western coun-tries (World Health Organization [WHO], 2005). Metabolic syndrome 
(MetS) is a clinical entity that encompasses several risk factors for CVD 
(Semenkovich, 2006; N Pischon et al., 2008). MetS consists of a combination 
of impaired glucose regulation, abdominal obesity, dyslipidemia, and high 
blood pressure (Eckel et al., 2005). It is estimated that around a quarter of the 
world’s adult population is affected by MetS (Cameron et al., 2004).
It is generally accepted that the origin of all those metabolic disorders is 
a “pro-inflammatory” state derived from excessive caloric intake and over-
nutrition, and, perhaps, other chronic inflammatory conditions (Dandona 
et al., 2004; Ghanim et al., 2004; Hotamisligil, 2006). This hypothesis 
states that this pro-inflammatory state, being characterized by an increase in 
inflammatory mediators such as tumor necrosis factor alpha (TNF-α), 
induces insulin resistance, promoting further inflammation through an 
increased free fatty acid (FFA) concentration (essentially, derived from 
lipolysis) and a resultant interference with the anti-inflammatory effects of 
insulin. This pro-inflammatory state also leads to an increase in oxidative 
stress, with the potential to impair several crucial biological mechanisms 
(Tripathy et al., 2003; Dandona et al., 2004; Hansel et al., 2004). Therefore, 
insulin resistance could act as the common link among all the components of 
MetS (Dandona et al., 2002, 2004).
Oxidative stress is defined as a persistent imbalance between the produc-
tion of highly reactive molecular species (e.g., reactive oxygen species [ROS], 
reactive nitrogen species [RNS]) and anti-oxidant defenses (Halliwell, 1991). 
There is an increase in ROS in the pre-diabetic stage, likely due to obesity-
related elevations of FFA, and several studies have shown that reversal of the 
imbalance between ROS and anti-oxidants improves insulin resistance in mice 
and humans (Ceriello and Motz, 2004; Wright et al., 2006).
Periodontitis is a generally chronic disorder characterized by the break-
down of the tooth-supporting tissues and the impaired host inflammatory 
immune response. This condition is due fundamentally to an ecological 
imbalance between the normal microbial biofilm on teeth and the host tissues 
(Newman, 1974). There is increasing evidence linking periodontitis to sys-
temic diseases (Kuo et al., 2008), such as diabetes (Herring and Shah, 2006), 
rheumatoid arthritis (Pischon et al., 2008b), and, especially, CVD (Ford et al., 
2007; Paquette et al., 2007; Fardi and Papadimitriou, 2008)—hence the 
search for factors that may explain such relationships. A potential factor 
which could increase insulin resistance is the production of oxidative stress-
enhancing ROS in affected periodontal tissues (Battino et al., 1999; Chapple 
and Matthews, 2007).
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Therefore, our goal in this review is to analyze the published 
data to consider the hypothesis for a potential relationship 
between MetS and periodontitis, with oxidative stress acting as 
a putative link between both conditions.
MetAboLIc syNdroMe: cUrreNt deFINItIoNs
MetS as originally described (Reaven, 1988) is a combination of 
obesity, hypertension, impaired glucose tolerance or diabetes, 
hyperinsulinemia, and dyslipidemia (elevated triglycerides 
and decreased high-density lipoprotein-cholesterol [HDL-C] 
levels). These same features are also considered as risk factors 
for atherosclerosis, therefore leading to the deduction that 
MetS constitutes a risk for coronary heart disease (Ninomiya  et al., 
2004).
Insulin resistance is a condition in which normal amounts of 
insulin are inadequate to elicit a normal response from fat, mus-
cle, and liver cells (Di Filippo et al., 2007). This condition leads 
to an eventual hyperglycemia which has systemic deleterious 
effects, mainly acting over the vas-
culature. The current definitions of 
the main disorders presenting with 
impaired glucose regulation are 
shown in Table 1.
There are currently several def-
initions in use to characterize 
MetS. The most frequently used 
are from the WHO, the US National 
Cholesterol Education Program 
Adult Treatment Panel III (NCEP-
ATP-III, 2001) (Table 2), and the 
International Diabetes Federation 
(IDF, 2005) (Table 3). Other defi-
nitions come from the European 
Group for the Study of Insulin Resis-
tance (Balkau et al., 2002) and the 
National Heart, Lung, and Blood 
Institute/American Heart Associa-
tion (Grundy et al., 2004).
The rationale for the WHO def-
inition was that a diabetic or pre-
diabetic individual who developed 
certain CVD risk components 
should be considered as suffering 
from MetS, because this is a well-
defined clinical entity. The WHO 
stated that each component con-
veyed a greater CVD risk, and 
their mixed occurrence increased 
the overall risk. Therefore, the rea-
son for diagnosing MetS was to 
identify persons at undue risk of 
CVD (Reaven, 2006). Subse-
quently, the goal of the NCEP-ATP 
III was focused less on type 2 dia-
betes and more on CVD risk, and 
thus, an additional aim was to 
focus on primary prevention in persons with multiple risk fac-
tors. The NCEP-ATP III considered MetS to represent multiple, 
interrelated factors that raise CVD risk, and stated that the root 
causes were overweight or obesity, physical inactivity, and 
genetic factors (Reaven, 2006). The most recent characterization 
of MetS was the result of a consensus conference organized by 
the IDF. This definition gives more importance than others to 
ethnic differences in diagnostic criteria (IDF, 2005).
Nevertheless, there is currently some disagreement as to the 
precise definition of MetS (Reaven, 2005; Grundy, 2006). Some 
authors consider that a diagnosis of MetS as a defined entity is 
not clinically useful (Kahn et al., 2005; Kahn, 2007, 2008). 
They describe some weak features of this syndrome. With 
respect to definition, the criteria are ambiguous or incomplete, 
the rationale for thresholds in clinical or laboratory parameters 
is not clear, the inclusion of diabetes in the definition is ques-
tionable, and a clear basis for including or excluding other car-
diovascular risk factors does not exist. Moreover, they argue that 
the cardiovascular risk associated with the syndrome seems to 
table 1. Current Definitions of Disorders with Impaired Glucose Regulation (World Health Organization, 
1999; American Diabetes Association, 2005; Nichols et al., 2007)
 
Type 2 Diabetes
Impaired Glucose 
Tolerance (IGT)
 
Impaired Fasting Glycemia (IFG)
•  Single raised glucose reading 
with symptoms,
or
•  Raised values on 2 occasions, 
of either fasting plasma 
glucose ≥ 7.0 mmol/L 
(126 mg/dL) or with a 
glucose tolerance test, 
2 hrs after an oral dose of 75 
g, a plasma glucose ≥ 
11.1 mmol/L (200 mg/dL)
•  2-hour glucose levels of 
140-199 mg per dL 
(7.8-11.0 mmol/L) on a 
75-g oral glucose tolerance 
test
•  Fasting glucose may be 
either normal or mildly 
elevated
•  Fasting glucose level > 5.6 
mmol/L (100 mg/dL) and 
< 6.9 mmol/L (125 mg/dL)
table 2. Definitions of Metabolic Syndrome by WHO and NCEP-ATP-III
WHO (Alberti and Zimmet, 1998) NCEP-ATP-III Criteria (NCEP-ATP, 2001)
Presence of DM, IGT, IFG, or insulin resistance, 
and 2 of the following features:
At least three of the following:
• blood pressure ≥ 140/90 mm Hg;
•  dyslipidemia, defined by TG ≥ 1.695 mmol/L 
and/or HDL-C ≤ 0.9 mmol/L in males or ≤ 1.0 
mmol/L in females;
•  central obesity, defined by waist:hip ratio 
> 0.90 in males or > 0.85 in females, and/or 
BMI* > 30 kg/m2;
•  microalbuminuria, defined by a urinary albumin 
excretion ratio ≥ 20 mg/min or albumin: 
creatinine ratio ≥ 30 mg/g
•  central obesity, measured as waist 
circumference ≥ 102 cm in males or ≥ 88 cm 
in females;
• TG ≥ 1.695 mmol/L (150 mg/dL);
•  HDL-C < 40 mg/dL in males or < 50 mg/dL 
in females;
• blood pressure ≥ 130/85 mmHg;
•  fasting plasma glucose ≥ 6.1 mmol/L 
(110 mg/dL)
* BMI, body mass index; DM, diabetes mellitus; HDL-C, high-density lipoprotein-cholesterol; IFG, 
impaired fasting glycemia; IGT, impaired glucose tolerance; TG, triglycerides.
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be no greater than the sum of its 
parts, and the treatment for MetS 
is not different from that for each 
of its components. These authors 
consider that the hypothesis of 
insulin resistance as a unifying 
cause is uncertain.
Therefore, it will be necessary 
to unify the diagnostic criteria to 
establish the actual prevalence and 
influence of this condition over 
local (e.g., periodontitis) and sys-
temic diseases (e.g., CVD).
oXIdAtIVe stress ANd 
MetAboLIc syNdroMe
As previously mentioned, insulin 
resistance plays a key role in the 
pathophysiology of MetS. Several inflammatory mediators are 
involved in the pathogenesis of insulin resistance, with TNF-α 
having apparently the strongest effect (Tilg and Moschen, 
2008). The most important tissues involved in the pathogenesis 
of this disorder are muscle and adipose tissue.
When caloric intake exceeds energy expenditure, the resultant 
substrate-induced increase in citric acid cycle activity generates 
an excess of ROS (Maddux et al., 2001). Oxidative stress alters 
the intracellular signaling pathway, inducing insulin resistance 
(Evans et al., 2003). Recently, a study with a murine model 
(Matsuzawa-Nagata et al., 2008) has shown that the pathways for 
ROS production and oxidative stress are up-regulated in both the 
liver and adipose tissue of mice fed a high-fat diet before the onset 
of insulin resistance. Moreover, the increased ROS production 
was previous to the TNF-α and FFA elevation in the plasma and 
liver. In agreement with this hypothesis, insulin resistance is asso-
ciated with reduced intracellular anti-oxidant defense in humans 
(Bruce et al., 2003), and anti-oxidants improve insulin sensitivity 
(Paolisso and Giugliano, 1996; Ceriello, 2000).
There is a spectrum of potential molecular and cellular damage 
derived from ROS production. Lipoprotein modification takes 
place in the absence (glycation) and presence (glycoxidation) of 
oxygen (Baynes and Thorpe, 2000), and these modifications can 
alter their structure and function (Jenkins et al., 2004). These 
modified lipoproteins are formed through a non-enzymatic 
process in which sugars bind to free amino groups of the lipopro-
tein (Njoroge and Monnier, 1989; Basta et al., 2004).
Lipid peroxidation is the formation of lipid peroxides via an 
enzymatic and/or a non-enzymatic mechanism. ROS resulting from 
hyperglycemia are thought to contribute to the initiation of lipid 
peroxidation (Cosentino et al., 1997). Once formed, lipid peroxides 
undergo a series of complex reactions, ultimately binding chemi-
cally to proteins. Thus, lipoxidation is the covalent binding of 
products of lipid peroxidation reactions to proteins (Esterbauer 
et al., 1991, 1992; Spiteller, 1998; Jenkins et al., 2004).
Several studies have demonstrated a relationship between 
MetS and oxidative stress in humans. Thus, systemic oxidative 
stress is significantly higher in persons with MetS compared 
with non-obese normolipidemic individuals. Some HDL-C sub-
fractions possess significantly lower specific anti-oxidative 
activity in affected persons than their counterparts in control 
individuals, and this attenuated anti-oxidative activity of HDL-C 
subfractions correlates with systemic oxidative stress and insulin 
resistance (Hansel et al., 2004). In agreement with these results, 
persons suffering from MetS have poor anti-oxidant status and 
significantly increased oxidative stress (serum lipid peroxide 
level), compared with those without MetS (Sharma et al., 2005). 
Moreover, obese adults with MetS have significantly higher 
plasma concentrations of oxidized-LDL-C, compared with obese 
adults without this condition (Van Guilder et al., 2006). By con-
trast, Sjogren et al. (2005) found no significant differences for 
plasma oxidized-LDL-C and urinary 8-iso-prostaglandin F2α 
(8-iso-PGF2α) between healthy and MetS men.
Advanced glycation end-products (AGE) are important 
markers for oxidative stress, and their endogenous secretory 
receptor (esRAGE) in plasma, as a soluble decoy receptor for 
AGE, is significantly and inversely correlated with components 
of the MetS, including body mass index, blood pressure, triglyc-
eride, glycated hemoglobin (HbA1c), and an insulin resistance 
index (Koyama et al., 2005).
MetAboLIc syNdroMe ANd PerIodoNtItIs
In spite of extensive clinical research on MetS, relatively little 
attention has been directed to its possible relationship to perio-
dontitis. The available data come from epidemiological studies. 
In a group of 1315 affected individuals (30-92 yrs old), the 
prevalence of MetS was higher among individuals with advanced 
periodontitis (66.7%) than in periodontally healthy individuals 
(48.8%) (Borges et al., 2007). Analysis of data from 13,710 
participants in the NHANES III (Third National Health and 
Nutrition Examination Survey) showed a direct relationship 
between periodontitis and the prevalence of MetS (37% in 
those with severe periodontitis vs. 18% in those with mild or no 
periodontitis), and, particularly, higher prevalence of obesity 
(48-54% vs. 31%), hypertension (51-56% vs. 27%), and high 
table 3. Definition of Metabolic Syndrome According to the International Diabetes Federation 
(IDF, 2005)
Raised TG ≥ 150 mg/dL or Specific Treatment
Central obesity 
(defined as waist 
circumference**)
Reduced HDL-C* < 40 mg/dL in males < 50 mg/ dL in females or specific treatment 
+
2 of the 
following 
parameters
Raised BP systolic BP ≥ 130 or diastolic BP ≥ 85, or treatment of 
previously diagnosed hypertension
Raised FPG FPG ≥ 100 mg/dL or previously diagnosed type 2 diabetes.
OGTT is recommended but not necessary
* HDL-C, high-density lipoprotein-cholesterol; BP, blood pressure; FPG, fasting plasma glucose; OGTT, 
oral glucose tolerance test; TG, triglycerides.
** Their values are specific for ethnicity. If BMI (body mass index) is > 30 Kg/m2, central obesity can 
be assumed and waist circumference does not need to be measured.
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glucose levels (18-24% vs. 8%) were stated to be in the moder-
ate to severe periodontitis group compared with the mild perio-
dontitis or periodontally healthy group (D’Aiuto et al., 2008). 
In another paper (Shimazaki et al., 2007), larger waist circum-
ference, decreased HDL-C levels, and higher fasting glucose 
levels were associated with significantly higher odds ratios 
(OR) for greater pocket depth values (1.8, 2.2, and 2.2, respec-
tively) in 584 Japanese women.
To study the pathological aspects behind this epidemiologi-
cal relationship, one must analyze the different aspects of MetS 
in relation to periodontitis.
Impaired Glucose regulation and Periodontitis
There are many papers on the relationship between diabetes 
and periodontal disease (Liu et al., 2006; Graves et al., 2007; 
Mealey and Ocampo, 2007; Nishimura et al., 2007; Preshaw 
et al., 2007), and evidence of the relationship between a major 
marker of diabetes, glycated hemoglobin (HbA1c), and perio-
dontal parameters (Grossi et al., 1997; Iwamoto et al., 2001; 
Stewart et al., 2001; Tsai et al., 2002; Navarro- Sanchez et al., 
2007) exists.
As previously mentioned, one of the main common factors 
between both diseases is oxidative stress. The main studies 
relating oxidative stress as a common feature in periodontitis 
and diabetes are shown in Table 4. With respect to neutrophil 
function, there is no remarkable variation in oxidative burst 
and chemotaxis (De Toni et al., 1997; Christgau et al., 1998; 
Fontana et al., 1999). However, a decreased superoxide-dis-
mutase (SOD) activity, an anti-oxidant enzyme, in gingival 
tissue from persons with periodontitis but without diabetes 
(Akalin et al., 2008), compared with those with periodontitis 
and diabetes, might be explained by a potential compensating 
mechanism in this enzymatic system derived from hyperglyc-
emia. Individuals with periodontitis and diabetes also show 
decreased activity of one pro-oxidant enzyme, myeloperoxi-
dase, in gingival crevicular fluid (GCF), compared with those 
without diabetes (Gonçalves et al., 2008). Analysis of these 
data suggests a dysregulation in oxidative balance derived from 
neutrophil leukocytes, with a concomitant influence by both 
conditions. Nevertheless, a critical point in the assessment of 
neutrophil function is the diversity and variability in assays, so 
concluding data in this respect are difficult to obtain.
With respect to substances derived from oxidative damage, a 
correlation exists between plasma lipid peroxidation and perio-
dontal parameters in diabetic individuals (Collin et al., 2000; 
Sonoki et al., 2006). Moreover, there is increasing evidence of 
the deleterious effect of AGE on the pathogenesis (Schmidt 
et al., 1996) and progression of periodontitis (Takeda et al., 
2006), and this effect could be mediated through the highly 
expressed RAGE in periodontal tissues (Katz et al., 2005). This 
last study found a similar expression of RAGE between diabetic 
and non-diabetic individuals by immunohistochemistry, but a 
higher mRNA level in diabetic individuals. A possible alterna-
tive splicing of mRNA from this molecule may explain this 
finding, and could elucidate differences in this regard between 
periodontal tissues and other body structures.
dyslipidemia and Periodontitis
In recent years, several papers have considered the possible 
relationships between periodontitis and lipid parameters 
(Table 5). In general, although differences among studies exist, 
there is an association between increased LDL-C and triglycer-
ide levels, as well as decreased HDL-C levels, and periodontitis. 
It is important to note the potential importance of oxidative 
stress in this relationship, because of the correlation existing 
between clinical periodontal status and plasma levels of 
anti-oxidized-LDL-C antibodies (Montebugnoli et al., 2004). 
Nevertheless, another report found no association between oxi-
dized LDL-C and periodontal status (Türkoğlu et al., 2008). More 
research focused on the relationship between lipid peroxidation 
markers and periodontitis is warranted.
Hypertension and Periodontitis
The first report (Perlstein and Bissada, 1977) relating high 
blood pressure with periodontitis in animals found hyperplasia/
hypertrophy in the blood vessel walls from a chronically irri-
tated gingiva in hypertensive and obese-hypertensive rats. 
However, hypertension alone was not a significant factor. In 
contrast to this, another report (Leite et al., 2005), in which an 
experimental ligature-induced periodontitis model was used in 
spontaneously hypertensive and normotensive rats, found that 
the ligated sides in the experimental group showed moderate to 
severe collagen degradation in the alveolar process, compared 
with mild degradation in controls.
The main studies relating hypertension and periodontitis in 
humans are shown in Table 6. In general, there is increasing 
evidence of a relationship between high blood pressure and 
more severe periodontal parameters, in such a way that indi-
viduals with hypertension show a poorer periodontal state 
(Wakai et al., 1999; Khader et al., 2003; Al-Emadi et al., 2006; 
Gołebiewska et al., 2006; Holmlund et al., 2006; Salcedo-
Rocha et al., 2006; Engström et al., 2007), and periodontitis can 
negatively influence certain features of hypertension, such as an 
increase in the left ventricular mass (Angeli et al., 2003; 
Valentaviciene et al., 2006).
obesity and Periodontitis
Recently, two exhaustive reviews have presented the main stud-
ies relating obesity and periodontitis (Pischon et al., 2007; Saito 
and Shimazaki, 2007), and readers are referred to these valuable 
sources. Briefly, both papers corroborate an influence of body 
mass index (BMI) and other anthropometric parameters on 
periodontitis, although the authors consider several limitations 
in previous studies. In the future, it would be necessary to use 
samples stratified by age, gender, and ethnicity, as well as by 
number of remaining teeth, to confirm those results, and in addi-
tion to design longitudinal studies to verify a potential causal 
relationship. Both reviews also consider adipocytokines as a 
potential link between obesity and periodontitis. In this respect, 
several reports relate leptin, adiponectin, and resistin with perio-
dontitis, and are discussed below.
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table 4. Main Studies about Oxidative Stress Parameters in Diabetes Mellitus and Periodontitis in Humans
 
Reference
 
Study Population
 
Country
Age 
Range (yrs)
Assessment of 
Periodontitis
 
Oxidative Parameters
 
Major Results
Akalin 
et al., 2008
17 type-2 DM persons 
with CP (DMCP 
group)
18 type-2 DM PH 
persons (DMPH 
group)
17 persons with CP 
(CP group)
17 PH control 
individuals (PH 
group)
Turkey 29-68 •  ≥ 30% ABL* and 
≥ 3 teeth with PD 
≥ 5 mm
•  Gingival SOD 
(measured as U/
mg-protein)
•  Gingival SOD activity 
was decreasing in this 
order: DMPH > PH > 
DMCP > CP, with 
significant difference 
between DMCP and 
DMPH, and between CP 
and DMCP and PH
•  Inverse correlation 
between gingival SOD 
activity and PD, AL, 
GI, PI
De Toni 
et al., 1997
Fontana 
et al., 1999
All participants 
with CP:
40 DM persons
40 SH individuals
Italy 45-64 •  ≥ 16 remaining 
teeth, excluding 
3rd molars
•  Criteria for CP 
are not detailed
•  NADPH-oxidase 
activity in PMN by two 
different assays
• Neutrophil chemotaxis
•  Depending on the 
technique used, = NADPH-
oxidase activity in both 
groups, or 
< in DM persons
•  No differences in 
chemotaxis between 
groups
Christgau 
et al., 1998
Persons with moderate 
to severe CP:
20 DM persons
20 SH control 
individuals
Germany 30-67 •  ≥16 remaining 
teeth
•  ≥ 6 teeth with PD 
≥ 4 mm
•  Oxidative burst 
response of PMN to 
TNF-α and FMLP, 
before and after non-
surgical periodontal 
therapy
•  No differences between 
both groups in relation 
to oxidative burst 
response.
•  > oxidative burst 
response after 
periodontal therapy, in 
both groups
Gonçalves 
et al., 2008
Persons with CP:
20 type-2 DM persons 
with inadequate 
metabolic control
20 SH persons
Brazil 30-60 •  ≥ 15 natural 
teeth, excluding 
3rd molars and ≥ 
4 teeth with ≥ 1 
sites exhibiting PD 
≥5 mm, clinical 
AL ≥4 mm, visible 
plaque and BOP
•  Total salivary 
peroxidase activity
•  Myeloperoxidase 
(MPO) antivity in the 
GCF
•  < MPO activity in the 
GCF for the DM persons, 
at both baseline and 
after periodontal therapy
Collin et al., 
2000
45 type-2 DM persons
77 control persons
Finland 45-64 •  ≥ 1 periodontal 
pockets > 4 mm
•  Salivary MMP-8 and 
MMP-9 activities
•  Plasma lipid 
peroxidation
•  Poor metabolic control in 
DM group was 
associated with > 
salivary MMP-8 but < 
plasma lipid 
peroxidation
Sonoki et al., 
2006
Persons with 
periodontitis:
5 type-2 DM persons
6 SH persons
Japan > 40 •  ABL > 50% for ≥ 
1 tooth and PD > 
4 mm for ≥ 1 
tooth
•  Plasma lipid 
peroxidation (LPO)
•  Serum anti-
malondialdeyde-
modified LDL-C (anti-
MDA-LDL-C)
•  > LPO in DM compared 
with control persons, but 
no differences in anti-
MDA-LDL-C between 
both groups
•  < LPO in DM persons 
after periodontal 
therapy, but not in 
control individuals
(continued)
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table 4. (continued)
 
Reference
 
Study Population
 
Country
Age 
Range (yrs)
Assessment of 
Periodontitis
 
Oxidative Parameters
 
Major Results
Katz et al., 
2005
Persons with CP:
8 well-controled 
type-2
DM persons
14 SH persons
USA Not 
detailed
•  AL ≥ 30% with 
BOP in the 
remaining 
dentition
•  Protein expression 
(immunohistochemistry) 
and mRNA 
transcription by  
RT-PCR of RAGE from  
gingival biopsies
•  < anti-MDA-LDL-C in both 
groups after periodontal 
therapy
•  In DM persons, BOP 
tended to correlate with 
LPO
•  Immunohistochemical 
staining for RAGE in 
endothelium and basal 
and spinous layer of 
gingival epithelium in 
both groups
•  mRNA for RAGE was 
increased in DM persons
Takeda et al., 
2006
97 DM persons:
69 CP
28 SH
Japan 57.8 ± 12.1
(mean ± SD)
•  ≥ 10 functional 
teeth
•  1 tooth with AL > 
5 mm
• plasma AGE •  Plasma AGEs showed a 
positive correlation to 
periodontal deterioration 
(% of teeth with AL > 5 
mm) in DM persons
Yoon et al., 
2004
52 DM persons
40 SH persons
Germany 57 ± 13,
41 ± 14,
respectively
(mean ± 
SD)
•  Periodontal 
parameters not 
detailed
•  Analysis of AGE in 
saliva by nuclear 
magnetic resonance 
(NMR) spectroscopy
•  Saliva in DM persons 
contained AGE, and 
these products were 
associated with 
approximal plaque index
* ABL, alveolar bone loss; AGE, advanced glycation end-products; AL, attachment loss; BOP, bleeding on probing; periodonti-
tis, CP, chronic periodontitis; DM, diabetes mellitus; FMLP, formyl-methyonyl-leucyl-phenylalanine; GCF, gingival crevicular 
fluid; GI, gingival index; LPO, lipid peroxidation; PD, probing depth; PH, periodontally healthy; PI, plaque index; RAGE, 
receptor for AGE; RT-PCR, reverse-transcription polymerase chain-reaction; SD, standard deviation; SH, systemically 
healthy; SOD, superoxide-dismutase; TNF-α, tumor necrosis factor alpha. 
AdIPocytoKINes ANd PerIodoNtItIs
The role of adipose tissue in the regulation of glucose homeostasis 
through insulin action has led to its consideration as a new endo-
crine organ. Adipocytes secrete a diversity of molecules, cur-
rently named adipocytokines, which influence metabolic and 
immune functions. Leptin and adiponectin are the most studied. 
Another molecule weakly related to adipocytes in humans, but very 
important in the inflammatory response and insulin resistance, is 
resistin (Juge-Aubry et al., 2005; Koerner et al., 2005; Rosen 
and Spiegelman, 2006).
Leptin and Periodontitis
Leptin negatively regulates the appetite and weight, mainly 
through a central mechanism involving the hypothalamus. It 
also can interact with other hormones, such as insulin (Margetic 
et al., 2002; Guzik et al., 2006). Obesity appears to be a condi-
tion of relative leptin resistance, with an elevated circulating 
level of leptin reported due to an enlarged fat mass (El-Haschimi 
et al., 2000). Moreover, there is some evidence that leptin is 
involved in the pathogenesis of atherosclerotic vascular disease 
(Wolk et al., 2004).
A decreasing leptin level in GCF and gingival tissue is asso-
ciated with a more deteriorated periodontal status (Johnson and 
Serio, 2001), and smokers also show reduced GCF leptin levels 
(Bozkurt et al., 2006), suggesting a protective role of leptin for 
the periodontium. The relationship between GCF and serum 
levels of leptin has been recently reported (Karthikeyan and 
Pradeep, 2007a,b). GCF leptin levels are proportional to BMI. 
In periodontitis, there is a significant negative correlation 
between GCF and serum leptin concentration, and these changes 
are significantly associated with increasing clinical attachment 
loss. The two possible mechanisms to explain this inverse cor-
relation are shown in Fig. 1. By contrast, a study of periodontitis 
and MetS (Borges et al., 2007) found a higher serum leptin level 
in healthy and chronic gingivitis individuals than in those with 
initial/moderate or advanced periodontitis. It is difficult to draw 
conclusions from this disagreement, because this latter study 
used pooled data from healthy and MetS individuals.
Adiponectin and Periodontitis
Adiponectin levels remain relatively constant in normal circum-
stances (Trujillo and Scherer, 2005), but are decreased in 
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table 5. Main Studies about Plasma Lipid Parameters and Periodontitis in Humans
 
Reference
 
Study Participants
 
Country
Age Range 
(yrs)
Assessment of 
Periodontitis
Serum Lipid 
Parameters
 
Major Results
Cutler 
et al., 1999
6 SH PH
7 SH CP
6 well-controlled  
DM and PH
5 well-controlled  
and CP
5 poorly-controlled  
DM and PH
6 poorly-controlled  
DM and CP
USA 28.2 ± 4.6
42.9 ± 11.9
52 ± 6.4
65.8 ± 6.3
45 ± 5.3
42.5 ± 13.6
respectively
(mean ± SD)
•   ≥ 4 periodontal 
pockets with  
≥ 6 mm with BOP 
and radiographic 
evidence of ABL* 
> 50%
•   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   TG levels tended to be 
higher in those groups 
without CP
Wakai 
et al., 1999
517 males
113 females
Japan 23-83 •   CPITN •   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   > HDL-C level was 
associared with < CPITN
Lösche 
et al., 2000
39 moderate CP
40 PH control 
individuals
Germany 50-60 •   > 3 pockets with a 
PD ≥ 4 mm
•   Total cholesterol
•   LDL-C
•   TG
•   > Total cholesterol, LDL-C 
and TG for CP group
Noack 
et al., 2000
56 individuals with 
IGT
17 individuals with 
hyperlipidemia
27 SH control 
individuals
Germany 40-70 •   PD
•   AL
•   BOP
•   PI
•   Total cholesterol
•   TG
•   > No. sextants with 
increased PD in 
hyperlipidemia group 
compared with control 
individuals
•   + correlation between 
serum TG levels and PD in 
the overall sample
Wu 
et al., 2000
10,146 participants 
from NHANES III
USA 40.37 ± 
17.28
(mean ± SD)
•   No disease: no 
tooth examined 
with PD ≥ 2 mm or 
AL ≥ 3 mm
•   Mild CP, ≥ 1 
examined tooth 
with PD ≥ 2 mm or 
AL ≥ 3
•   CP ≥ 1 tooth with 
PD ≥ 3 mm or AL 
≥ 4 mm
•   Total cholesterol
•   HDL-C
•   There was a weak 
association between 
cholesterol level and 
periodontal status
•   There was no association 
between HDL-C and 
periodontal status
Katz et al., 
2001
151 individuals 
diagnosed as 
having CHD, DM 
or hypertension
943 SH individuals
Israel 26-53 •   CPITN •   Total cholesterol
•   TG
•   Persons with 
hypercholesterolemia had 
more severe CP, 
according to CPITN score
•   There was no association 
between TG and 
periodontal status
Katz et al., 
2002
9421 military men
1169 military 
women
Israel 19-61 •   CPITN •   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   A CPITN score of 4 is 
strongly associated 
with total and LDL-C 
cholesterol and negatively 
associated with HDL-C 
in men
Craig et al., 
2003
25 PH persons
44CP persons
USA 29.9 ± 1.1
38.7 ± 1.3
respectively
(mean ± SD)
•   ≥ 20 teeth and ≥ 
4 sites with PD > 3 
mm and ≥ 4 sites 
with AL > 3 mm
•   Total 
cholesterol
•   HDL-C
•   LDL-C
•   TG
•   > Total cholesterol and 
LDL-C levels for CP group
•   < HDL-C for CP group
•   > TG levels for CP 
persons, but without a 
statistical significance
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table 5. (continued)
 
Reference
 
Study Participants
 
Country
Age Range 
(yrs)
Assessment of 
Periodontitis
Serum Lipid 
Parameters
 
Major Results
Saito et al., 
2003
179 men Japan 50-54 •   ≥ 10 remaining 
teeth
•   ABL (panoramic Rx)
•   Total cholesterol
•   HDL-C
•   TG
•   There was a negative 
correlation between HDL-C 
levels and ABL
Joshipura 
et al., 2004
377 PH men
91 CP men
USA 43-80 •   The participant 
reported being 
professionally 
diagnosed with CP
•   LDL-C •   LDL-C showed a positive 
correlation with CP, and 
this result persisted after 
subsequent adjustment for 
dietary factors
Montebugnoli 
et al., 2004
63 men with CHD
50 healthy men
Italy 40-65 •   CPSS (clinical 
periodontal sum 
score): the sum of 
the No. sites with 
PD ≥ 4mm, No. 
gingival sites with 
BOP, visible 
suppuration on 
probing, No. 
furcation lesions 
exceeding grade 1
•   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   Serum 
antibodies 
against oxidized 
LDL-C (anti-Ox-
LDL-C)
•   There was a significant 
relationship between CPSS 
and anti-Ox-LDL-C
•   There was no association 
between periodontal status 
and total cholesterol, LDL-C, 
HDL-C, or TG levels
Morita et al., 
2004
133 persons from 
Japanese rural 
communities, with 
and without CP
Japan NA •   CPI •   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   > TG level for CP group
•   < HDL-C for CP group, but 
without a statistical 
significance
Lösche et al., 
2005
32 persons with CP 
receiving 
periodontal 
treatment
Germany 23-69 •   Criteria for 
periodontitis are 
not detailed
•   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   No association between 
lipid parameters and BOP, 
PD, or AL
•   No variation in lipid levels 
before/after periodontal 
therapy (6-8 weeks later)
Machado 
et al., 2005
30 moderate to 
severe CP
30 PH control 
individuals
Brazil 43.3 ± 9,2
44.3 ± 9,7
respectively
(mean ± SD)
•   ≥ 2 sites with PD 
≥ 5 mm
•   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   No significant differences 
between groups
Nishimura 
et al., 2006
131 non-obese 
type-2 DM 
persons
Japan 36-84 •   Periodontal 
examination was 
not performed
•   HDL-C
•   LDL-C
•   TG
•   Association between LDL-C 
and serum antibody titer to 
Porphyromonas gingivalis
Valentaviciene 
et al., 2006
140 women
121 men
Lithuania 38
(mean)
•   CPITN •   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   No association between 
lipid parameters and 
CPITN
Furukawa et 
al., 2007
100 type-2 DM 
persons
Japan 29-77 •   PD •   Total cholesterol
•   HDL-C
•   Total cholesterol was 
significantly correlated with 
mean PD
•   HDL-C was inversely 
correlated with PD (but no 
statistical significance)
Nibali et al., 
2007
302 persons with 
severe 
periodontitis 
(aggressive and 
chronic forms)
183 PH control 
individuals
United 
Kingdom
38-48 •   Aggressive period
•   (Armitage 1999)
•   Chronic period:
      ≥ 20 teeth and 
50% of sites 
exhibiting PD ≥ 
5mm and marginal 
ABL > 30%
•   Total cholesterol
•   HDL-C
•   LDL-C
•   Cholesterol/
HDL-C ratio
•   TG
•   LDL-C levels were 
significantly increased in 
periodontitis persons
•   HDL-C levels were 
significantly decreased in 
periodontitis persons
•   Cholesterol/HDL-C ratio 
was significantly higher in 
periodontitis persons
(continued)
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table 5. (continued)
 
Reference
 
Study Participants
 
Country
Age Range 
(yrs)
Assessment of 
Periodontitis
Serum Lipid 
Parameters
 
Major Results
Oz et al., 
2007
51 periodontitis 
persons assigned 
to the treatment 
or control groups
Turkey 36-66 •   > 3 sites with PD ≥ 
4 mm
•   Total cholesterol
•   HDL-C
•   LDL-C
•   TG
•   There was a significant 
decrease in cholesterol 
and LDL-C levels after 
treatment (3 months later)
Türkoğlu et al., 
2008
72 persons, divided 
into healthy 
control 
individuals, 
PH-EHT, G-EHT, 
CP-EHT
Turkey 44.83± 
8.4454.35± 
11.14 
49.71±7.30 
54.38±6.76 
respectively
(mean ± SD)
•   ≥ 4 non-adjacent 
teeth with sites 
with AL ≥ 4mm 
and PD ≥ 5 mm, 
BOP at >50% of 
sites
•   Oxidized LDL •   No differences in 
oxidized-LDL-C between 
groups
* ABL, alveolar bone loss; AL, attachment loss; BOP, bleeding on probing; CHD, coronary heart disease; CP, periodontitis; CPITN, community 
periodontal index of treatment needs; DM, diabetes mellitus; EHT, essential hypertension; G, gingivitis; HDL-C, high-density lipoprotein-choles-
terol; LDL-C, low-density lipoprotein-cholesterol; NA, not available; NHANES III, Third National Health and Nutrition Examination Survey; PD, 
probing depth; PH, periodontally healthy; PI, plaque index; SD, standard deviation; SH, systemically healthy.
(continued)
table 6. Published Reports about Arterial Hypertension and Periodontitis in Humans
 
Reference
 
Study Participants
 
Country
Mean Age  
(yrs ± SD)
Assessment of 
Periodontitis
Vascular 
Parameters
 
Major Results
Al-Emadi 
et al., 2006
210 moderate or 
severe CP
210 PH or mild CP
USA 46.95
(± 16.17)
•   ≥ 20 remaining 
teeth
•   Moderate/severe 
CP: mean ABL* 
≥ 2.5 mm
•   Self-reported HBP •   > HBP prevalence in 
subjetcs with moderate 
to severe ABL (34.3% 
vs. 7.6%)
Angeli 
et al., 2003
104 persons with 
EHT
Italy 57
(± 10)
•   CPITN •   Echocardiography •   Association between > 
CPITN score and LVM
Engström 
et al., 2007
54 persons with 
known HBP
141 persons with 
diastolic BP > 90 
mmHg during study
195 control persons
Sweden Mean age in 
case groups: 
49 and 54, 
respectively
•   No. sites ≥ 5 
(excluding the third 
molar)
•   Diastolic and 
systolic blood 
pressure
•   > No. sites ≥ 5 mm in 
HBP persons
•   Association between 
prevalence of deep 
periodontal pockets 
and BP status
Gołebiewska 
et al., 2006
47 persons HBP
57 persons, 
myocardial 
infarction (MI), 
treated with 
angioplasty
Poland 50-90 (range) •   OHI index
•   Russell’s PI and CPI
•   Tooth loss 
according to 
Eichner’s class
•   Previous medical 
diagnosis
•   < OHI and poorer 
periodontal status in 
persons with HBP, 
specially those with MI
Higashi 
et al., 2008
32 CP+, HBP-
20 control 
individuals
38 CP+, HBP+
24 CP-, HBP+
Japan 25 ± 3, 
26 ± 3, 
respectively
54 ± 13, 56 
± 12, 
respectively
•   Self-reported 
periodontal status
•   Forearm blood 
flow (FBF) 
response to 
acetylcholine 
(ACh)
•   < FBF response to ACh 
in both CP groups
•   Periodontal therapy ↑ 
ACh-induced 
vasodilation in CP 
individuals
Holmlund 
et al., 2006
3,352 persons with 
history of HBP or 
myocardial 
infarction
902 control 
individuals
Sweden 45 ± 17 •   Periodontal disease 
severity index 
(PDSI), combining 
ABL and BOP
•   HBP was defined 
as drug treatment 
for this disease
•   Association between 
severity of CP and No. 
of periodontal pockets 
with HBP
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table 6. (continued)
 
Reference
 
Study Participants
 
Country
Mean Age  
(yrs ± SD)
Assessment of 
Periodontitis
Vascular 
Parameters
 
Major Results
Khader et al.., 
2003
603 participants 
from general 
population
Jordan 15-65 (range) •   PD, AL, PI
•   Gingival recession
•   Questionnaire for  
general health
•   Having HBP was 
significantly associated 
with increased AL and 
gingival recession
Salcedo-Rocha 
et al.., 2006
363 persons with 
overweight-obesity, 
HBP or DM, or a 
combination of them
Mexico 50.05 ± 
9.70
•   Periodontal criteria 
not detailed
•   Blood pressure •   In the sample, HBP 
group showed the 
poorest periodontal 
status
Türkoğlu et al., 
2008
72 individuals, 
divided into 
healthy control 
individuals, 
PH-EHT, G-EHT, 
CP-EHT
Turkey 44.83 ± 8.44, 
54.35 ± 
11.14, 49.71 
± 7.30, 54.38 
± 6.76, 
respectively
•   ≥ 4 non-adjacent 
teeth with sites with 
AL ≥ 4mm and PD ≥ 
5 mm, BOP at 
>50% of sites
•   Serum IgM 
and IgG 
anti-cardiolipin
•   > mean IgM anti-CL 
levels and > 
prevalence of persons 
with IgM anti-CL+ in 
CP-EHT group
Valentaviciene 
et al., 2006
140 women
121 men
Lithuania 38 •   CPITN •   Echocardiography •   < LVM index in PH/G 
persons compared to CP
Wakai et al., 
1999
517 males
113 females
Japan 23-83 •   CPITN •   Blood pressure •   > systolic BP was 
associated with > CPITN
* ABL, alveolar bone lose; AL, clinical attachment level; anti-CL, anticardiolipin antibodies; BOP, bleeding on probing; BP; blood pressure; CP, 
periodontitis; CPI, community periodontal index; CPITN, community periodontal index of treatment needs; DM, diabetes mellitus; EHT, essen-
tial hypertension; FBF, forearm blood flow; G, gingivitis; HBP, hypertension; LDL-C, low-density lipoprotein-cholesterol; LVM, left ventricular 
mass; OHI, oral hygiene index; PD, probing depth; PH, periodontally healthy; PI, plaque index.
Figure 1. Increased serum leptin levels in periodontitis. Two putative 
explanations have been proposed. First, gingival inflammation would 
result in vasodilation, which might increase the net rate of leptin 
removal from the gingiva and increase serum leptin levels. The second 
hypothesis states that serum leptin levels rise as a body defense mecha-
nism to counteract periodontal inflammation (according to Karthikeyan 
and Pradeep, 2007b).
obesity, insulin resistance, and diabetes, and in cardiovascular 
disease with increa sing severity (Matsuzawa et al., 2004). This 
reduction appears to precede these disorders, and low adiponec-
tin levels have been shown to predict the development of insulin 
resistance and type 2 diabetes (Spranger et al., 2003; Yamamoto 
et al., 2004). Thus, adiponectin has a key role in the develop-
ment of MetS.
Currently, there is no report of adiponectin in periodontal 
tissues or GCF. By an in vitro approach, adiponectin acts as 
a potent negative regulator of the osteoclast formation 
induced by Aggregatibacter actinomycetemcomitans lipopol-
ysaccharide (LPS). Therefore, adiponectin could exert an 
anti-inflammatory effect in periodontitis sites, and thereby 
have a negative influence over the onset and progression of 
periodontitis (Yamaguchi et al., 2007). In humans, two 
recent studies (Furugen et al., 2008; Saito et al., 2008) have 
found that serum adiponectin levels tended to decrease in 
Japanese persons with periodontitis, albeit not significantly. 
Moreover, adiponectin levels were negatively correlated 
with mean attachment loss, but not mean probing depth or 
percentage of sites bleeding on probing. Another study 
(Iwamoto et al., 2003) found that serum adiponectin levels 
did not change significantly after periodontal therapy. 
However, small sample size, lack of a control group, and a 
longer period for additional measures are relevant limita-
tions in this study.
resistin and Periodontitis
In humans, resistin is mainly secreted by monocytes, macro-
phages, and bone marrow, but also by adipocytes. It has a potent 
pro-inflammatory action. This molecule has been associated 
with insulin resistance in mice (Koerner et al., 2005). Two 
recent studies confirm the role of this molecule in periodontitis; 
serum resistin levels are higher in persons with periodontitis 
than in control individuals, and there is a positive correlation 
with bleeding on probing (Furugen et al., 2008; Saito et al., 
2008).
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oXIdAtIVe stress As A PoteNtIAL  
LINK betweeN PerIodoNtItIs ANd  
MetAboLIc syNdroMe
As previously mentioned, oxidative stress is one of the main 
factors studied to explain the pathophysiological mechanisms of 
inflammatory conditions, such as MetS and periodontitis. A 
recent and exhaustive review (Chapple and Matthews, 2007) has 
described the complex role of oxidative stress in relation to 
periodontal breakdown. It seems that peripheral blood neu-
trophil hyperactivity in chronic and aggressive periodontitis 
exists as a constitutional element (Matthews et al., 2007a,b), 
rather than being entirely the result of peripheral priming by 
cytokines or plaque bacterial LPS. In addition, there may be 
possible baseline hyperactivity, with low-level extracellular ROS 
release in the absence of any exogenous stimulus in persons 
with periodontitis (Gustafsson and Asman, 1996; Gustafsson 
et al., 1997; Fredriksson et al., 1998; Matthews et al., 2007b).
There is increasing evidence for compromised anti-oxidant 
capacity in periodontal tissues and fluids, independent of smok-
ing, and increased AGE levels in persons with type 2 diabetes 
and in smokers, which are risk factors for periodontitis. Such 
oxidation products can increase neutrophil adhesion, chemo-
taxis, and priming in hyper-reactive neutrophils, and might aug-
ment the damaging effects of the resultant oxidative stress 
(Brock et al., 2004; Palmer et al., 2005; Panjamurthy et al., 
2005). In addition to this, the up-regulation of pro-inflammatory 
transcription factors, such as NF-κB and activating protein-1, 
in inflamed periodontal tissues contributes to reduced glutathione 
depletion and ROS generation (Chapple, 1997; Janssen-
Heininger et al., 2000).
It is important to emphasize the influence of periodontitis on 
serum and/or plasma oxidative markers in humans. Several stud-
ies have demonstrated an increase in products of oxidative dam-
age in peri pheral blood from persons with periodontitis compared 
with control individuals (Battino et al., 2001; Montebugnoli et al., 
2004; Baltacioglu et al., 2008). Moreover, it is evidence of a 
decreased anti-oxidant capacity in persons with periodontitis, 
evaluated by different assays (Chapple et al., 2002, 2007; Battino 
et al., 2003; Brock et al., 2004; Panjamurthy et al., 2005; 
Baltacioglu et al., 2006; Akalin et al., 2007; Konopka et al., 2007; 
Zilinskas et al., 2007).
Therefore, it might be argued that this increased pro-oxidative 
state and decreased anti-oxidant capacity in persons with perio-
dontitis could facilitate the onset of a decrease in insulin sensi-
tivity, which could be aggravated by a high fat diet in these 
persons. This is in agreement with the previously mentioned 
report which demonstrated that an increase in ROS production 
precedes insulin resistance (Matsuzawa-Nagata et al., 2008). 
Conversely, the presence of MetS or any of its components in a 
previously periodontally healthy person could facilitate a pro-
oxidant state which would diminish anti-oxidant capacity of the 
periodontal tissues, and the response of these tissues to bacterial 
challenge could be impaired. The presence of a high RAGE 
expression in periodontal tissues (Katz et al., 2005) is an impor-
tant finding supporting the sensitivity of these tissues to prod-
ucts derived from oxidative damage. Moreover, AGE may 
Figure 2. Hypothetic role of oxidative stress as a link between perio-
dontitis and metabolic syndrome (MetS).
promote apoptosis in osteoblasts (Alikhani et al., 2007a) and 
fibroblasts (Alikhani et al., 2007b), and this might have an influ-
ence on alveolar bone homeostasis and the progression of perio-
dontitis. This way, it is plausible to draw a patho-physiological 
picture in which a bidirectional influence exists between both 
conditions, with oxidative stress as a common link (Fig. 2).
Leptin and adiponectin appear as potential candidates to 
influence in a positive or negative manner, respectively, over the 
pro-oxidative state in periodontitis and MetS. Leptin has been 
demonstrated to have a predominantly pro-oxidative effect 
(Bouloumie et al., 1999; Maingrette and Renier, 2003; Suzuki 
et al., 2003; Beltowski et al., 2004). The increased serum leptin 
levels existing in persons with periodontitis, possibly in an 
attempt to modulate the immune response, could be one of the 
factors that induces oxidative stress and accelerates the onset of 
insulin resistance. This increased oxidative stress could facili-
tate a relative hypoadiponectinemia (Hattori et al., 2005; Soares 
et al., 2005; Katsuki et al., 2006), like that presenting in persons 
with periodontitis, which could also decrease the protection 
against oxidative damage, since this adipocytokine has been 
demonstrated to have a protective effect against oxidative stress 
(Nakanishi et al., 2005; Barazzoni et al., 2007). This picture is 
ideal for the onset of features comprising MetS (Fig. 3).
Figure 3. Proposed roles of leptin and adiponectin as putative media-
tors in the oxidative imbalance enhancing periodontitis and insulin 
resistance.
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coNcLUsIoNs
The evidence reviewed indicates that there is a need for further 
research concerning the possible relationships between MetS and 
periodontitis, in relation to both local and systemic health and 
disease. But according to the available reviewed data, we can 
propose some pathological mechanisms that could explain this 
relationship. Adipocytokines may act as a link between both con-
ditions, and relevant questions arise which could guide future 
research: (1) Can gingival keratinocytes or any cell type from 
gingiva or periodontal ligament express leptin, adiponectin, and/
or resistin, or any of their respective receptors? (2) How do these 
molecules interact with other cytokines in periodontal tissues and 
influence oxidative stress derived from periodontal breakdown? 
(3) What is the relationship between serum and GCF levels of 
these molecules in systemically healthy and MetS persons, with 
or without chronic gingivitis and/or periodontitis?
Oxidative stress could be a common mechanism in the devel-
opment of several features related to both MetS and periodontitis, 
and perhaps an interaction between both conditions may result 
in a worse evolution of both of them. To elucidate the potential 
association between both conditions, several approaches are 
suggested:
(1) Design large-scale studies to assess biomarkers of oxidative 
stress and anti-oxidant defenses in persons suffering from 
MetS, with and without periodontitis at several grades of 
severity, to facilitate comparisons between both conditions 
and to determine whether periodontitis can affect redox state 
in persons with MetS. Use of the new definition of this condi-
tion (IDF, 2005), applied to different ethnic groups, would be 
an important element, with the aim of achieving more reliable 
conclusions.
(2) Analysis of biomarkers of oxidative stress, to obtain a more 
complete view of the potential interactions between both 
conditions. All such markers should be analyzed in relation 
to each component of MetS in persons with and without 
periodontitis.
(3) Design an intervention study, in which the influence of 
periodontal therapy (conservative and surgery) on biomarkers 
of oxidative stress in persons with MetS would be assessed.
All data derived from these and other such approaches would 
increase the knowledge of the possible interrelationships among 
periodontitis, MetS, and CVD, with the natural aim of improv-
ing their diagnosis, treatment, and, ultimately, prevention.
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